RNA-Induced immunity against a rat sarcoma

Production of cytotoxic antibody to a benz(a)pyrene-induced sarcoma in mice receiving xenogeneic antitumor immune RNA

“…Following their report, Rigby prolonged the survival of mice bearing Ehrlich ascites tumors by administering syngeneic spleen cells previously incubated with RNA from the spleens of mice immunized with this tumor [38]. Londner et al demonstrated a slowing of the growth of transplants of a spontaneously arising sarcoma in rats treated by the intraperitoneal injection of RNA extracted from the spleens of rats immunized with the tumor being treated [27]. Kennedy et al reported the protection of C3H mice against transplants of a benz(a)pyrene-induced sarcoma by footpad injections of RNA extracted from the lymph nodes and spleens of C57BL mice im-munized with this tumor [24].…”

Conversion of human lymphocytes to antitumor immune reactivity by xenogeneic and allogeneic imune RNA detected by leukocyte-adherence inhibition tests

“…I-RNA has been shown to transfer immune reactivity to tuberculin [7,27,38], sheep red blood cells [1,3], allogeneic tissues [25,30,34], and several carcinogen-induced tumors [2,16,24,31,32]. These immune responses have been detected by skin testing [15], inhibition of macrophage migration [7,28,38,40], and lymphocyte blastogenesis [5][6][7].…”

Anti-tumour cytotoxicity of poly(A)-containing messenger RNA isolated from tumour-specific immunogenic RNA

“…Less used assays were designed to detect migration-inhibition factor (Schlager et al, 1975;Thor and Dray, 1973) and lymphoblastogenesis (Deckers et al, 1975;Dodd et al, 1973). The in vivo models for mediation of specific tumour cytotoxicity produced results demonstrating temporary tumour regression (Alexander et al, 1967;Schlager et al, 1975), decreased rate (Londner et al, 1968), or inhibition of tumour growth (Ramming and Pilch, 1970;Skinner et at., 1976) and protection against tumours with prolonged survival (Kennedy et al, 1969;Rigby, 1969).…”